Abstract 466P
Background
The daycare caters to numerous cancer patients. Patient satisfaction is a surrogate estimator of the quality of healthcare. Determination of the factors responsible for this will help to improve patient care delivery.
Methods
Women with breast or ovarian malignancies undergoing chemotherapy at the medical oncology daycare unit from 1st January 2023 to 1st April 2023 were invited to complete the PSS questionnaire anonymously. The PSS tool is an abbreviated 28 item questionnaire related to administrative services, medical team members and the treating consultant. The response options comprised a 5-point Likert scale. The raw scores were linearly transformed to a 0-100 scale and patients scoring more than 60 were considered as satisfied.
Results
A total of 117 patients participated in the study. There was a high level of overall satisfaction rate (93.2%). Availability of social support and health insurance were significant determinants of patient satisfaction (p=0.0043 and p=0.0006 respectively). The median waiting time was 3 hours with a satisfaction rate of 84%. The satisfaction rate for secretarial assistance, medical staff and the treating physician were 94%, 94% and 93.2% respectively. The patients’ likelihood of returning to our daycare for and recommending it to others were 97.4% and 96.6% respectively.
Conclusions
Ensuring availability of social support, provision of health insurance and effective patient-physician communication is likely to increase patient satisfaction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract